CIPLA Cipla Q1 FY27 results (Apr–Jun 2026) and concall
Cipla reported its highest-ever Q1 FY27 revenue of INR 7,119 crores, up 2% YoY (4% adjusted), driven by strong performance in India and North America. The EBITDA margin stood at 16.7%, impacted by one-time inventory write-offs and war-related costs, but management expects sequential improvement towards its FY27 target of 18.5-20%. The company reaffirmed its $1 billion US exit run rate target for FY27, supported by key respiratory and peptide launches.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 2.3%, net profit down 39.2% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 +0% | 6,541 −3% | 7,119 +2% |
| EBITDA | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 −37% | 955 −38% | 1,192 −33% |
| Net profit | 1,575 | 1,214 | 1,292 | 1,353 | 674 −57% | 543 −55% | 786 −39% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
